Similar articles

• The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.

  Robb MA, Racoosin JA, Sherman RE, Gross TP, Ball R, Reichman ME, Midthun K, Woodcock J. Robb MA, et al. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:9-11. doi: 10.1002/pds.2311. Pharmacoepidemiol Drug Saf. 2012. PMID: 22262587 No abstract available.
• Computerized medical device tracking--ways to comply with SMDA (Safe Medical Devices Act of 1990).

  Landis D. Landis D. Healthc Inform. 1992 Jul;9(7):36, 38, 40-2. Healthc Inform. 1992. PMID: 10119858 No abstract available.
• Postmarketing surveillance of medical devices--filling in the gaps.

  Resnic FS, Normand SL. Resnic FS, et al. N Engl J Med. 2012 Mar 8;366(10):875-7. doi: 10.1056/NEJMp1114865. Epub 2012 Feb 14. N Engl J Med. 2012. PMID: 22332950 No abstract available.
• Thresholds of toxicological concern based on structure-activity relationships.

  Munro IC, Ford RA, Kennepohl E, Sprenger JG. Munro IC, et al. Drug Metab Rev. 1996 Feb-May;28(1-2):209-17. doi: 10.3109/03602539608994000. Drug Metab Rev. 1996. PMID: 8744597 Review. No abstract available.
• Strategies for postmarketing surveillance of drugs for rare diseases.

  Kesselheim AS, Gagne JJ. Kesselheim AS, et al. Clin Pharmacol Ther. 2014 Mar;95(3):265-8. doi: 10.1038/clpt.2013.218. Epub 2013 Nov 5. Clin Pharmacol Ther. 2014. PMID: 24193169 Review.